Detection of a t(4;14)(p16;q32) in two cases of lymphoma showing both the immunophenotype of chronic lymphocytic leukemia

Cancer Genetics and Cytogenetics

Volumn 200, Issue 2, 2010, Pages 170-174

  Bacher, Ulrike ^a   Haferlach, Torsten ^b   Schnittger, Susanne ^b   Weiss, Tamara ^b   Burkhard, Oswald ^c   Bechtel, Britta ^d   Kern, Wolfgang ^b   Haferlach, Claudia ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^c Oncological Practice Worms   (Germany)

^d Dr med Heinz Weischer   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; CD5 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FLUDARABINE; IMMUNOGLOBULIN LAMBDA CHAIN; MITOXANTRONE; RITUXIMAB; SOMATOMEDIN;

AGED; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CHROMOSOME 11P; CHROMOSOME 14; CHROMOSOME 16; CHROMOSOME 4; CHROMOSOME 8; CHROMOSOME BANDING PATTERN; CHROMOSOME DELETION; CHROMOSOME REARRANGEMENT; CHRONIC LYMPHATIC LEUKEMIA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC VARIABILITY; HUMAN; IMMUNOPHENOTYPING; KARYOTYPING; LEUKOCYTOSIS; LYMPHOCYTIC INFILTRATION; LYMPHOMA; MALE; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; PROTEIN EXPRESSION; SPLENOMEGALY; TRISOMY 12;

AGED; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 4; FEMALE; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOPHENOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, B-CELL; MALE; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; TRANSLOCATION, GENETIC;

EID: 77953787254     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2010.03.009     Document Type: Article

References (20)

1. Dicker F., Schnittger S., Haferlach T., Kern W., Schoch C. Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: a study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood 2006, 108:3152-3160.
2. Dohner H., Stilgenbauer S., Benner A., Leupolt E., Krober A., Bullinger L., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000, 343:1910-1916.
3. Hallek M., Cheson B.D., Catovsky D., Caligaris-Cappio F., Dighiero G., Dohner H., et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines. Blood 2008, 111:5446-5456.
4. Cavazzini F., Hernandez J.A., Gozzetti A., Russo R.A., De A.C., Tiseo R., et al. Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis. Br J Haematol 2008, 142:529-537.
5. Haferlach C., Dicker F., Schnittger S., Kern W., Haferlach T. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. Leukemia 2007, 21:2442-2451.
6. Fonseca R., Barlogie B., Bataille R., Bastard C., Bergsagel P.L., Chesi M., et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004, 64:1546-1558.
7. Avet-Loiseau H., Attal M., Moreau P., Charbonnel C., Garban F., Hulin C., et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007, 109:3489-3495.
8. Keats J.J., Reiman T., Maxwell C.A., Taylor B.J., Larratt L.M., Mant M.J., et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 2003, 101:1520-1529.
9. Moreau P., Attal M., Garban F., Hulin C., Facon T., Marit G., et al. Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials. Leukemia 2007, 21:2020-2024.
10. Bergsagel P.L., Kuehl W.M. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005, 23:6333-6338.
11. Santra M., Zhan F., Tian E., Barlogie B., Shaughnessy J. A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood 2003, 101:2374-2376.
12. Marango J., Shimoyama M., Nishio H., Meyer J.A., Min D.J., Sirulnik A., et al. The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood 2008, 111:3145-3154.
13. Lauring J., Abukhdeir A.M., Konishi H., Garay J.P., Gustin J.P., Wang Q., et al. The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity. Blood 2008, 111:856-864.
14. Vatsveen T.K., Brenne A.T., Dai H.Y., Waage A., Sundan A., Borset M. FGFR3 is expressed and is important for survival in INA-6, a human myeloma cell line without a t(4;14). Eur J Haematol 2009, 83:471-476.
15. Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M. Characterization of MYC translocations in multiple myeloma cell lines. J Natl Cancer Inst Monogr 2008, 25-31.
16. Forconi F., Rinaldi A., Kwee I., Sozzi E., Raspadori D., Rancoita P.M., et al. Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion. Br J Haematol 2008, 143:532-536.
17. van Dongen J.J., Langerak A.W., Bruggemann M., Evans P.A., Hummel M., Lavender F.L., et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003, 17:2257-2317.
18. Stilgenbauer S., Bullinger L., Lichter P., Dohner H. Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leukemia 2002, 16:993-1007.
19. Garand R., Avet-Loiseau H., Accard F., Moreau P., Harousseau J.L., Bataille R. t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma. Leukemia 2003, 17:2032-2035.
20. Rassenti L.Z., Jain S., Keating M.J., Wierda W.G., Grever M.R., Byrd J.C., et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 2008, 112:1923-1930.